NCT01352858View on ClinicalTrials.gov

Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA)

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Rheumatoid Arthritis
Interventions
DRUG

TolDC

Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.

DRUG

Arthroscopy & saline irrigation alone

Trial Locations (1)

NE2 4HH

Newcastle University, Newcastle upon Tyne

All Listed Sponsors
collaborator

Arthritis Research UK

OTHER

collaborator

Newcastle-upon-Tyne Hospitals NHS Trust

OTHER

lead

Newcastle University

OTHER

NCT01352858 - Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis (AutoDECRA) | Biotech Hunter | Biotech Hunter